- ImmuniMed inc., is a clinical stage Biopharmaceutical company, engaged in a phase 2 clinical trial of a novel Antibody treatment for C Difficile Infection (CDI). C Difficile bacteria annually infects and kills approximately 500,000 and 30,000 people respectively in North America alone, at a cost to the healthcare system estimated greater than $3 billion. A treatment to solve a problem of this magnitude is often termed a Blockbuster Drug.
- ImmuniMed Inc. has approved Patents for our CDI treatment in Canada, the U. S. and EU.
- Our Antibody treatment has already cured several patients in our ongoing phase 2 clinical trial and results from initial Proof of Concept trials were 94% effective in treating CDI patients.
- Certain favorable tax advantages may be available.
- After successful completion of the phase 2 trial, we anticipate our treatment will attract interest from large pharma companies, providing a possible quick exit strategy.
- Phase 3 is the final trial in the drug registration process, which we believe can be fast tracked by the FDA as an unmet medical need treatment, speeding up the registration process.
- ImmuniMed Inc anticipates having the capacity to produce enough Antibodies to treat all of the world’s cases of C Difficile Infection.
- We believe our Antibody treatment is better than alternatives for several reasons. Competing C Difficile experimental treatments include new antibiotics, vaccines and variations on Fecal Microbiota Transplant (FMT) therapy.
- We believe ImmuniMed Inc. has high upside value potential. Fidaxomicin, priced at $5,600 per dose is becoming the standard of care as Vancomycin loses efficacy due to Antimicrobial Resistance. North America alone has some 500,000 cases of CDI annually.
- We believe this is a unique opportunity for a clinical stage Pharma company and a Blockbuster treatment. It will be a great achievement when successful and make a statement to the international pharmaceutical community. We hope you will consider joining us on this exciting ride as it plays out.
Antibiotics have resistance and side effects issues. The present Standard of Care to treat CDI is antibiotics, which are unsuccessful in some 30% to 40% of cases. New trial antibiotics have shown minimal improvement and are very expensive.
Vaccines are less effective for the most susceptible C Difficile patients, who are seniors with generally lesser immune system capacity. Who to vaccinate will also pose an interesting question. Pfizer recently announced the failure of their experimental C Diff vaccine to reach its successful end point of preventing C Diff infection.
FMT therapy is only allowed for multiple recurrent CDI patients. That is, to qualify as a trial and future patient, you must have failed the Standard of Care treatment three times before being eligible. Furthermore the transfer of pathogens in the treatment can not be ruled out, with the first known death attributed to FMT occurring in June 2019.
Bonus Reason: Our treatment is not an antibiotic, which until now has been considered the only solution against bacterial infection. Antibiotic resistance issues gives safe and effective antibiotic alternatives high priority. For this reason we believe there is no question our Antibody Therapy will play a future role in the treatment of C Difficile infection.
John Hare
204-955-8495
941-221-2505